Overview
AOD 9604, or Anti-Obesity Drug 9604, is a synthetic peptide developed as a targeted fat-loss therapy. Derived from a modified fragment of human growth hormone (HGH), this peptide enhances fat metabolism without impacting insulin sensitivity or appetite. Unlike traditional weight-loss medications, AOD 9604 works by accelerating metabolic rate, promoting lipolysis, and inhibiting lipogenesis, all while preserving lean muscle mass.
Key Benefits of AOD 9604
Promotes Fat Burning: Stimulates lipolysis, releasing fat from fat cells.
- Inhibits Fat Storage: Prevents new fat formation through anti-lipogenic effects.
- Supports Cartilage and Joint Health: Enhances cartilage regeneration and may benefit osteoarthritis.
- No Impact on Blood Sugar Levels: Does not elevate blood glucose or insulin levels.
- Safe and Targeted Action: Minimal side effects with no stimulation of IGF-1.
How It Works
AOD 9604 consists of amino acids 177–191 from the growth hormone molecule, specifically targeting fat breakdown. By bypassing the HGH receptor, AOD 9604 stimulates fat metabolism and prevents fat formation independently. In animal studies, it has shown consistent fat reduction even in the absence of beta-3 adrenergic receptors, suggesting multiple mechanisms of action.
Clinical Applications
- Weight Management: Promotes fat loss without affecting appetite or muscle mass.
- Joint and Cartilage Regeneration: May aid cartilage repair and mitigate joint pain when combined with hyaluronic acid.
- Metabolic Health: Supports healthy body composition without altering insulin sensitivity.
Research and Evidence
- Fat Loss:
- Animal Studies: Obese mice treated with AOD 9604 showed marked fat reduction with no effect on food intake.
- Human Trials: In a 12-week study with 300 obese adults, the lowest-dose group lost an average of 2.8 kg.
- Cartilage and Joint Regeneration:
- Studies in rabbits demonstrated enhanced cartilage repair when combined with hyaluronic acid.
- Shown to reduce inflammation and improve joint function in osteoarthritis models.
- Heart and Metabolic Health:
- By improving fat metabolism, AOD 9604 indirectly supports cardiovascular health and may improve metabolic markers.
Dosage and Administration
- Weight Management: 0.2 ml (300 μg) subcutaneously daily for 20 days.
- Cartilage and Joint Health: 0.3–0.5 ml (500–750 μg) intra-articularly once a week for 4 weeks, then monthly for 5 months.
- Storage: Store frozen until first use. Once opened, refrigerate at 2°C – 8°C for up to 60 days.
Side Effects and Safety
- No increase in appetite or blood glucose.
- Low risk of antibody formation due to structural similarity to natural HGH.
- No stimulation of IGF-1, reducing risks associated with growth hormone therapies.
Product Information
- Product Name: AOD 9604 (1500 μg/ml, 4 ml vial)
- Supplied As: Injectable peptide
- Suggested Usage: For fat reduction and joint health. Best used in cycles.
Additional Research Highlights
- Chronic use in obese mice reduced body weight by over 50% with no effect on insulin sensitivity.
- Human trials showed consistent, steady weight loss without resistance buildup.
- Studies suggest potential benefits for cartilage repair, osteoarthritis relief, and cardiovascular health.
Molecular Details
- Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
- Molecular Formula: C78H123N23O23S2
- Molecular Weight: 1815.12 g/mol
- PubChem CID: 16131447
- CAS Number: 386264-39-7
References
[1] Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000.
[2] Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013.
[3] “Obesity drug codenamed AOD9604 highly successful in trials.” News-Medical.net, 2004.
[4] Zieba R. Review of antiobesity drugs and new compounds in development. Postepy Hig Med Dosw. 2007.
[5] Heffernan M, et al. Effects of GH fragment AOD9604 on lipid metabolism in obese and β3-AR KO mice. Endocrinology. 2001.
[6] Kwon DR, Park GY. Effect of intra-articular AOD9604 with or without hyaluronic acid in rabbits. Ann Clin Lab Sci. 2015.
[7] Jensen MD. New therapies in modifying cardiovascular risk. Obesity. 2006.
[8] Stier H, Vos E, Kenley D. Safety and tolerability of AOD9604. J Endocrinol Metab. 2013.
